Axa S.A. Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Axa S.A. acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 4th quarter, HoldingsChannel reports. The fund acquired 89,482 shares of the company’s stock, valued at approximately $1,686,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sterling Capital Management LLC lifted its stake in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares during the period. Caitlin John LLC lifted its position in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after buying an additional 918 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PCRX. Barclays boosted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Pacira BioSciences in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $26.67.

Pacira BioSciences Price Performance

PCRX stock opened at $24.90 on Friday. The firm has a 50 day simple moving average of $24.70 and a two-hundred day simple moving average of $22.05. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock has a market cap of $1.15 billion, a PE ratio of -12.27 and a beta of 0.56. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.